Status:
COMPLETED
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Lead Sponsor:
Eli Lilly and Company
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The s...
Eligibility Criteria
Inclusion
- Have Type 2 Diabetes
- Have HbA1c ≥7.0% (53 mmol/mol) to ≤10.5% (91 mmol/mol), as determined by the central laboratory at screening.
- Have been on stable diabetes treatment with metformin ≥1500 milligram (mg)/day during the 90 days prior to screening and maintained through randomization.
- Are of stable body weight (±5%) for at least 90 days prior to screening and agree to not initiate an intensive diet or exercise program during the study with the intent of reducing body weight, other than the lifestyle and/or dietary measures for diabetes treatment
Exclusion
- Have Type 1 Diabetes
- Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema, for example, laser photocoagulation or intravitreal injections of anti-vascular endothelial growth factor inhibitors.
- Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening, or between screening and randomization.
- Have a New York Heart Association functional classification IV congestive heart failure.
- Have an estimated glomerular filtration rate (eGFR) \<45 milliliter/minute (mL/min)/1.73 square meter (m²) or lower than the country-specific threshold for discontinuing metformin therapy per local label as determined by the central laboratory at screening.
- Have a serum calcitonin level of ≥35 nanogram/Liter (ng/L), as determined by the central laboratory at screening.
- Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years.
Key Trial Info
Start Date :
September 22 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 22 2025
Estimated Enrollment :
1698 Patients enrolled
Trial Details
Trial ID
NCT06045221
Start Date
September 22 2023
End Date
August 22 2025
Last Update
September 22 2025
Active Locations (131)
Enter a location and click search to find clinical trials sorted by distance.
1
Absolute Clinical Research
Phoenix, Arizona, United States, 85051
2
San Fernando Valley Health Institute
Canoga Park, California, United States, 91304
3
Neighborhood Healthcare Institute of Health
Escondido, California, United States, 92025
4
Velocity Clinical Research, Gardena
Gardena, California, United States, 90247